+86-28-82633987
EN
CN EN

Saikosaponin C

BP1241
20736-08-7
98%
Phytopurify
Saikosaponin C exhibits anti-HBV activity, it has the potential for therapeutic angiogenesis but is not suitable for cancer therapy, it also might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. It inhibited caspase-3 activation and caspase-3-mediated-FAK degradation, induced matrix metalloproteinase-2 (MMP-2)、vascular endothelial growth factor (VEGF) 、the p42/p44 mitogen-activated protein kinase (MAPK, ERK). Saikosaponin C is a member of the class of saikosaponins that is saikogenin E substituted by a 6-deoxy-alpha-L-mannopyranosyl-(14)-[beta-D-glucopyranosyl-(16)]-beta-D-glucopyranosyl group at position 3beta. It is a natural product isolated from the traditional Chinese herb, Radix Bupleuri and exhibits anti-HBV replication activity. It has a role as an anti-HBV agent and a plant metabolite.
Catalog No Package Original Price Price Inventory Quantity Operating
BP1241-20mg 20mg $86.00
BP1241-100mg 100mg $260.00
Chengdu Biopurify Phytochemicals Ltd.
Chengdu Biopurify Phytochemicals Ltd.

Related targets

Saikosaponin C Related Products

Product drug property prediction parameters

  • 266.9100

  • 2.9002

  • 2.9005

  • .0287

  • .6076

  • 1.1105

  • Low

  • 73.1988

  • 7.6034

  • No

  • No

  • No

  • No

  • No

  • No

  • 0.0

  • Yes

  • No

  • Yes

  • Yes